Invictus MD Announces Completion of its Commitment to Acquire 33.33% of Licensed Producer AB Laboratories Inc.
CANNABIS BUZZ

Invictus MD announces $40,000,000 Bought Deal Private Placement of Convertible Debentures and notice of intention to exercise option on Acreage Pharms

Invictus MD announces $40,000,000 Bought Deal Private Placement of Convertible Debentures and notice of intention to exercise option on Acreage Pharms   BUZ INVESTORS  Invictus MD announces $40,000,000 Bought Deal INVICTUS MD STRATEGIES CORP. (“Invictus MD” or the “Company”) (TSXV: IMH; OTC: IVITF; FRA: 8IS) announced today that it has engaged Canaccord Genuity Corp. and Eventus […]

Featured Video Play Icon
commodities

Talga CEO on Chemetall Deal and Becoming a Commercialized Graphene Player

Talga CEO on Chemetall Deal and Becoming a Commercialized Graphene Player   BUZ INVESTORS Chemetall Deal  Mark Thompson, Managing Director of Talga Resources Ltd (ASX: TLG), in an interview with InvestorIntel’s CEO Tracy Weslosky discuss their joint development agreement (JDA) with Chemetall, part of BASF, and their new, “mega [cobalt] project.” The deal with Chemetall […]

Invictus MD Announces $15,015,000 Bought Deal Private Placement of Units
Market Trends

$IMH Bought Deal Private Placement of Units

Invictus MD Announces $15,015,000 Bought Deal Private Placement of Units VANCOUVER, BC, February 10, 2017 – INVICTUS MD STRATEGIES CORP. (“Invictus MD” or the “Company”) (CSE: IMH; OTC: IVITF; FRA: 8IS) is pleased to announce today that it has entered into an agreement with Canaccord Genuity Corp. and Eventus Capital Corp. as co-lead underwriters (collectively, […]

AURORA CANNABIS ANNOUNCES $50G BOUGHT DEAL
Market Trends

$ACB $50G BOUGHT DEAL

AURORA CANNABIS ANNOUNCES $50G BOUGHT DEAL Aurora Cannabis Inc. has entered into an agreement with a syndicate of underwriters led by Canaccord Genuity Corp.to purchase, on a bought deal private placement basis 22,500,000 units of the company at a price of $2.25 per unit for aggregate gross proceeds of $50,625,000. Each unit will be comprised […]

Featured Video Play Icon
Video

InvestorIntel Interviews Dr. Zerbe of IntelGenx on Cialis deal

InvestorIntel Interviews Dr. Zerbe of IntelGenx on Cialis deal In this InvestorIntel interview, Dr. Horst G. Zerbe, President and CEO of IntelGenx Technologies Corp. (TSXV: IGX |OTCQX: IGXT), discusses the recent deal with Eli Lilly to manufacture Tadalafil (also known as Cialis®) as a pharmaceutical oral film, using IntelGenx’s VersaFilm™ technology. IntelGenx’s tadalafil oral film […]